Calciphylaxis, early identification and management: a report of 2 cases by Edwards, Harrison A. et al.
Introduction
Calciphylaxis, or calcific uraemic 
arteriolopathy (CUA), is a life-threatening 
calcification of arterioles leading to necrotic 
infarcts of the skin and subcutaneous tissue 
(panniculus adiposus) with a high potential to 
progress to bacterial sepsis and death.
The prevalence of CUA has been reported to 
be approximately 4.1% in patients with end-
stage renal disease (ESRD), with the 
reported incidence increasing over the past 
10 years1,2,3. This painful condition causes 
significant morbidity and has a one-year 
cause-specific mortality rate exceeding 
50%2. 
Risk factors include ESRD, 
hyperparathyroidism, female sex, Caucasian 
ethnicity, obesity, diabetes mellitus, time on 
dialysis, systemic corticosteroid use, 
hypoalbuminaemia, and corrected calcium 
phosphorus product >4.4 mmol2/L2 2,3,4. 
Here, we present two cases.
Patient Profiles
Patient 1 is a 57 year old Caucasian male 
with end-stage renal disease (ESRD) 
secondary to autosomal dominant polycystic 
kidney disease (ADPKD), and a dialysis 
vintage of 2 years. He was on peritoneal 
dialysis and taking calcitriol and calcium 
acetate. He was on warfarin for 
hypercoagulability.
His serum albumin level averaged 39 g/L in 
the six months before diagnosis, was 39 g/L 
at time of diagnosis, and averaged 44 g/L in 
the nine months following diagnosis. At time 
of diagnosis, adjusted calcium phosphorus 
product was 4.9 mmol2/L2. His CUA was 
diagnosed clinically.
Patient 2 is a 47 year old Caucasian female 
with ESRD secondary to ADPKD, and a 
dialysis vintage of 1.5 years. Six months prior 
to diagnosis of CUA, she had severe 
hyperphosphataemia and underwent 
parathyroidectomy. Prior to diagnosis she 
was on calcitriol and calcium acetate. She 
was on warfarin for a venous thrombosis. 
Her serum albumin level averaged 38 g/L in 
the six months before diagnosis, was 16 g/L 
at time of diagnosis, and averaged 23 g/L in 
the six months following diagnosis. At time of 
diagnosis, adjusted calcium phosphorus 
product was 4.7 mmol2/L2.
Her CUA started with 2 months of painful 
nodules involving her breasts, abdomen, and 
thighs. At this time, CT scanning was 
negative for calcification or ulceration of the 
soft tissue. Once she developed ulceration, 
her CUA was confirmed by biopsy.
Patient 1
Month 0: The patient exhibits painful violaceous plaques on the calves and thighs, with 
livedo reticularis rash on surrounding skin.  He has several lesions on the right thigh and 
two on the left thigh which are erythematous raised plaques of irregular shape.
Treatment: He was started on sodium thiosulphate with haemodialysis.
Month 2: A left shin lesion is erythematous with central necrosis of approximately 6 cm 
in diameter (left photo). A lesion on the right thigh has progressed to blistering and 
necrosis with eschar formation (right photo). 
Treatment: He is admitted to the hospital for pain control and daily dialysis with sodium 
thiosulphate.
Months 3-4: The left lateral lower leg wound exhibits diminishing eschar, and is mostly 
closed (left photo). The left posterior lower leg wound is healing slowly due to painful 
ulceration over 1 cm deep (not shown). The right thigh lesion shows necrosis with 
eschar formation (right photo). Induration around the lesions has decreased.
Treatment: Continued serial debridement, and use of calcium alginate and silver-
impregnated hydrating foam dressings for antimicrobial effect and exudate 
management.
Month 5: The right thigh wound shows minimal yellow slough. Overall, exudates have 
diminished. All wounds continue to improve (right photo).
Treatment: Wound swabs were sent for culture which was negative for infection. Gentle 
debridement was continued.
Month 9: An open area on the anterior surface of the left lower leg is pink at the base 
with some yellow slough and granulation tissue (left photo). 
Treatment: Silver-impregnated absorbent foam dressings were used to help draw 
moisture away from the wound. Dialysis with sodium thiosulphate was continued until 
month 11 when all wounds had closed.
Discussion
Patient 1 underwent the following treatments: He 
was taken off calcitriol and calcium acetate.  
Cinacalcet was started for control of 
hyperparathyroidism. Warfarin was changed to 
low-molecular weight heparin. The patient was 
counselled extensively to reduce phosphorus 
intake and improve nutrition, and to encourage 
adherence to his medical regimen. In addition to 
intensive wound care, he was converted from 
peritoneal dialysis to haemodialysis and continued 
on sodium thiosulphate for nearly 11 months until 
his wounds healed.
Patient 2 underwent the following treatments: She 
had had a recent parathyroidectomy. Calcitriol and 
calcium acetate were changed to cinacalcet and 
sevelamer. Warfarin was stopped. The patient was 
given  prednisone for one month, and two doses of 
pamidronate.  She was counselled to reduce 
phosphorus intake, and later she was started on 
nocturnal tube feeds, and supplemented with 
cyanocobalamin (B12), alpha-tocopherol (E), and 
zinc. Intensive wound care was performed with 
consultation from plastic surgery. Sodium 
thiosulphate was incorporated into the patient’s 
dialysis treatment. The wounds were healing, 
however, during month six she was re-admitted to 
hospital with sepsis and died.
In conclusion, the progression of CUA wounds 
highlights the need for rapid response when early 
signs appear. Skin biopsy can confirm clinical 
suspicion but is not without risk of infection and 
ulceration3,5. 
At this time, there are no prospective randomised 
controlled studies relating to CUA of which we are 
aware. Research is limited to observational and 
retrospective studies3. Future research is needed 
to improve diagnosis and treatment of this 
devastating condition.
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Patient 2
Month 2: After two months of painful subcutaneous nodules and despite treatment with 
sodium thiosulphate, these ulcerative lesions developed on the left anterior, lateral and 
posterior hip, and on the right posterior hip. They are deep with central necrosis. The 
largest is over 20 cm in diameter. Biopsy revealed thickened vascular walls with areas of 
calcification, and calcification involving the adipose soft tissue, consistent with CUA.
Month 3: The necrotic lesions have stopped expanding. There is surrounding erythema 
and induration. The patient has severe pain, even with only clothing touching the 
lesions.  She is losing weight and culture grows methicillin-resistant staphylococcus 
aureus.
Treatment: The patient was admitted to hospital for nocturnal tube feeding and wound 
care with gentle debridement and started on vancomycin for several weeks.
Month 4: Wounds show increased exudate, purulence, and sloughing. Eschar is 
forming. Infection is resolving.
Month 5: Granulation tissue is forming in most wounds. Infection has resolved.
Treatment: Wound vacuum use was avoided due to pain. The patient continued wound 
care at home.
Month 6: The wounds are healing. Enterobacter and candida were cultured.
Treatment: Wound care nurses applied silver sulfadiazine cream and a trypsin-based 
debriding cream daily. The patient continued on dialysis six times per week with sodium 
thiosulphate.
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